Qualtix Stock Brief
Amgen Inc. (AMGN) stock analysis: business quality, valuation, and entry timing
Amgen is one of the largest biotechnology companies, with medicines in bone health, cardiovascular disease, oncology, inflammation, and rare diseases. Strong cash flow is balanced against debt taken on for acquisitions and competition for older products. Public Qualtix model snapshot from 2026-10-26 for AMGN: business quality 60/100, a mixed model reading and valuation Fair. Today's verdict and Entry Timing are shown after a free sign-in.
Qualtix evaluates AMGN with a rules-based model that separates business quality, valuation, entry timing, red flags, and data confidence. The model scores first; AI explanations and the full Clean Brief help explain the result afterward.
Coverage note: Qualtix can analyze supported US stocks when SEC/FMP filing data is available. The 1,000+ stock universe refers to the daily screener used for discovery, not the full analysis limit.
AMGN public evidence metrics from the latest validated Qualtix snapshot
| Metric | Value | Why it matters | Source |
|---|---|---|---|
| Revenue growth | 12.8% | 3-year revenue CAGR | FMP, computed |
| FCF margin | 26.7% | Free cash flow divided by revenue | FMP, computed |
| Operating margin | 33.2% | Profitability margin | FMP, computed |
| Gross margin | 72.7% | Revenue retained after direct costs | FMP, computed |
| Return on capital (pre-tax) | 18.3% | Operating profit before tax, divided by equity plus debt | FMP, computed |
| ROE | 74.8% | Return on equity | FMP, computed |
| Cash and debt | Cash $14.0B / Debt $57.3B | Balance-sheet context | FMP, reported |
| TTM P/E | 27.7x | Price to trailing earnings | FMP, computed |
Qualtix view
- Business quality: 60/100, a mixed model reading.
- Valuation is currently labeled Fair, which the model weighs separately from business quality.
Today's verdict
- Today's model verdict and Entry Timing for AMGN update every market day and are shown after a free sign-in.
Data and snapshot dates
- Model snapshot date: 2026-10-26.
- Financial data through: 2026-06-30.
- Scored by the current Qualtix model.
- Data-confidence status: high.
What supports the current view
- Beta of 0.41 suggests lower market sensitivity than higher-beta alternatives.
What weakens the current view
- Business quality remains below the model's stronger-company threshold (60/100).
- Valuation is currently labeled Fair, so price still matters.
What changed
- Business Quality was unchanged from the previous snapshot.
What to research next
- Start with the weaker Business Quality signal (60/100): review revenue durability, margins, cash generation, and balance-sheet pressure.
- Compare AMGN's Fair valuation label with similar companies before treating price as a clear advantage.
- Compare AMGN with VRTX and ABBV to see whether the model edge is company-specific or sector-wide.
Follow Qualtix on X, TikTok, LinkedIn, YouTube.
Qualtix is for research and education only. It is not financial advice.